Most Recent
Thomson Geer picks up Hogan Lovells life sciences team
A life sciences and regulatory expert and her team have joined Thomson Geer following the shuttering of Hogan Lovells' Australian practice.
Judge questions need for solicitors in Jaguar class action discovery process
A judge has questioned the need for solicitors in a class action against Jaguar to be involved in discovery of internal investigations by the car maker when a technical referee is to be appointed.
Jones Day lures enviro partner from Norton Rose Fulbright
A top environmental lawyer has joined Jones Day as a partner in the firm's government regulation practice.
WiseTech shareholder class action loses bid for early discovery
A judge has declined an early bid for broad discovery in a shareholder class action against tech firm WiseTech, after hearing it would require the production of "truckloads" of irrelevant material.
Jones Day grows corporate practice with partners from Hogan Lovells
Global law firm Jones Day has recruited two corporate partners from rival Hogan Lovells to join its transactions team in Sydney.
High Court ends Commonwealth’s quest for $325M over generic Plavix ban
The High Court has settled a 16-year battle between the federal government and Sanofi over alleged excess subsidies it paid after a judge blocked the release of a generic version of blood thinner Plavix, saying its job was not to “resurrect” a dead case.
Pacific Werribee centre owners get preliminary trial in $200M defects spat
The co-owners of Pacific Werribee shopping centre in Victoria have won their bid for a preliminary trial in a suit against Probuild Constructions and several engineering companies over $200 million in alleged structural defects.
Jones Day recruits tax partner from Baker McKenzie
Longtime tax partner at Baker McKenzie has made the jump to Jones Day, joining the firm's Sydney office. 
‘Contingency on contingency’: Judge won’t halt IP dispute over Abilify generic
The Commonwealth has lost its bid to pause a long-running dispute over a generic form of brand drug Abilify while the High Court hears a different generic drug battle.
Government wants to stay 12-year-old dispute over Abilify generic
The Commonwealth has argued that a long-running dispute involving drug makers Otsuka, Bristol-Myers Squibb and Generic Health should be put on ice until the High Court rules in a separate matter.